347 (Hydroxychloroquine Sulfate 200 mg) Pill with imprint 347 is White, Round and has been identified as Hydroxychloroquine Sulfate 200 mg.
Hydroxychloroquine is not currently approved for use in the treatment of COVID-19; however, it is currently under investigation as a possible treatment option for coronavirus. We comply with the HONcode standard for trustworthy health information - Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment Princeton, NJ March 27, 2020: Sun Pharmaceutical Industries, Inc., USA, (SPII),a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (‘together Sun Pharma,’ It is supplied by Sun Pharmaceutical Industries Inc.. Hydroxychloroquine is used in the treatment of lyme disease, arthritis; dermatomyositis; malaria; malaria prevention; rheumatoid arthritis and belongs to the drug classes antimalarial quinolines, antirheumatics. Hydroxychloroquine is not currently approved for use in the treatment of COVID-19; however, it is currently under investigation as a possible treatment option for coronavirus. Hydroxychloroquine is used in the treatment of lyme disease, arthritis; Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials.“At Sun Pharma, we are resolute in our purpose to help people live healthier lives and stand united in our global fight against COVID-19,” Abhay Gandhi, CEO, Sun Pharma, North America, said in a company news release. “We are working with supply chain partners and wholesalers to help ensure swift delivery to areas where it will provide the most benefit as the clinical trials progress.”Hydroxychloroquine sulfate tablets manufactured by Sun Pharma are approved by the FDA for the treatment of a range of conditions including malaria, lupus erythematosus and rheumatoid arthritis.
Lupus Drug Prevents Low Heartbeat in High-Risk Newborns: Study Sun Pharma's U.S. unit donates hydroxychloroquine sulfate tablets in fight against coronavirus 1 Min Read March 27 (Reuters) - A subsidiary of India’s Sun Pharmaceutical … Sun Pharmaceutical Industries announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States. Available for Android and iOS devices. FDA Pulls Emergency Approval of Hydroxychloroquine for COVID-19
Hydroxychloroquine sulfate tablets manufactured by Sun Pharma are approved by the FDA for the treatment of a range of conditions including malaria, lupus erythematosus and rheumatoid arthritis.